311 related articles for article (PubMed ID: 30543737)
1. [A Case of Rheumatoid Arthritis Developed during Treatment with Nivolumab for Renal Cell Carcinoma].
Tomizawa M; Nakai Y; Maesaka F; Owari T; Hara R; Miyake M; Inoue T; Anai S; Tanaka N; Fujimoto K
Hinyokika Kiyo; 2018 Oct; 64(10):397-401. PubMed ID: 30543737
[TBL] [Abstract][Full Text] [Related]
2. [A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma].
Hattahara K; Yamasaki T; Sawada A; Tanigaki K; Endo S; Teramoto Y; Banno H; Fuchigami Y; Suzuki R; Fujiwara M; Hida T; Yoshino T; Kita Y; Goto T; Akamatsu S; Saito R; Kobayashi T; Inoue T; Ogawa O
Hinyokika Kiyo; 2019 May; 65(5):157-161. PubMed ID: 31247693
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Nivolumab-Induced Isolated Adrenocorticotropic Hormone Deficiency Presenting Dyspnea].
Ito K; Uchida T; Manabe Y; Miyazaki Y; Itoh H; Mishina M; Okuno H
Hinyokika Kiyo; 2018 Oct; 64(10):391-395. PubMed ID: 30543736
[TBL] [Abstract][Full Text] [Related]
4. Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Int J Clin Oncol; 2020 Apr; 25(4):705-712. PubMed ID: 31858306
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G;
BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884
[TBL] [Abstract][Full Text] [Related]
6. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.
Ikarashi D; Kato Y; Katagiri H; Takahara T; Uesugi N; Shiomi E; Sugimura J; Nitta H; Sugai T; Obara W
Int J Urol; 2018 Jun; 25(6):630-632. PubMed ID: 29693280
[TBL] [Abstract][Full Text] [Related]
7. [A CASE OF RENAL CELL CARCINOMA THAT ONCE NIVOLUMAB HAD BEEN EFFECTIVE IN METASTATIC LESION AND MADE PRIMARY TUMOR RESECTABLE].
Tsukahara S; Nagatomi Y; Otsubo S; Hasegawa S
Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):32-35. PubMed ID: 31956216
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.
Sarfaty M; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Eur Urol; 2018 Apr; 73(4):628-634. PubMed ID: 28807351
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
Vitale MG; Scagliarini S; Galli L; Pignata S; Lo Re G; Berruti A; Defferrari C; Spada M; Masini C; Santini D; Ciuffreda L; Ruggeri EM; Bengala C; Livi L; Fagnani D; Bonetti A; Giustini L; Hamzaj A; Procopio G; Caserta C; Sabbatini R
PLoS One; 2018; 13(7):e0199642. PubMed ID: 29979712
[TBL] [Abstract][Full Text] [Related]
10. Eruptive keratoacanthomas secondary to nivolumab immunotherapy.
Bednarek R; Marks K; Lin G
Int J Dermatol; 2018 Mar; 57(3):e28-e29. PubMed ID: 29318617
[No Abstract] [Full Text] [Related]
11. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Escudier B; Sharma P; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Gurney H; Donskov F; Peltola K; Wagstaff J; Gauler TC; Ueda T; Zhao H; Waxman IM; Motzer RJ;
Eur Urol; 2017 Dec; 72(6):962-971. PubMed ID: 28262413
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
[TBL] [Abstract][Full Text] [Related]
13. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report.
Dionese M; Pierantoni F; Maruzzo M; Bimbatti D; Deppieri FM; Maran M; Gardiman MP; Basso U
Anticancer Drugs; 2021 Feb; 32(2):222-225. PubMed ID: 32868643
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.
Thibault C; Vano Y; Soulat G; Mirabel M
Eur Heart J; 2018 Oct; 39(38):3553. PubMed ID: 30107497
[No Abstract] [Full Text] [Related]
15. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review.
Gamulin M; Nham E; Rkman D; Antunac Golubić Z; Likić R
Croat Med J; 2020 Aug; 61(4):326-332. PubMed ID: 32881430
[TBL] [Abstract][Full Text] [Related]
17. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer.
Fujiwara R; Inamura K; Yuasa T; Numao N; Yamamoto S; Masuda H; Kawauchi A; Takeuchi K; Yonese J
Int J Clin Oncol; 2020 Jan; 25(1):151-157. PubMed ID: 31522314
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab efficacy in leptomeningeal metastasis of renal cell carcinoma: a case report.
Bonomi L; Bettini AC; Arnoldi E; Chirco A; Ghilardi L; Manara O; Roscigno M; Da Pozzo LF; Tondini CA
Tumori; 2020 Dec; 106(6):NP76-NP78. PubMed ID: 32041500
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment.
Tabei T; Natsume I; Kobayashi K
Int J Urol; 2017 Sep; 24(9):708-710. PubMed ID: 28734029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
